vs
Protalix BioTherapeutics, Inc.（PLX）与SES AI Corp（SES）财务数据对比。点击上方公司名可切换其他公司
Protalix BioTherapeutics, Inc.的季度营收约是SES AI Corp的2.0倍（$9.1M vs $4.6M），Protalix BioTherapeutics, Inc.净利率更高（-60.3% vs -373.5%，领先313.1%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-11.1M）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
SES是卢森堡的通信卫星运营商，为全球的广播电视机构、内容提供商、互联网服务供应商、移动与固网运营商，以及各类政府与公共机构提供视频传输和数据连接服务。
PLX vs SES — 直观对比
营收规模更大
PLX
是对方的2.0倍
$4.6M
净利率更高
PLX
高出313.1%
-373.5%
自由现金流更多
PLX
多$12.7M
$-11.1M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $4.6M |
| 净利润 | $-5.5M | $-17.0M |
| 毛利率 | 49.4% | 11.3% |
| 营业利润率 | -51.1% | -387.7% |
| 净利率 | -60.3% | -373.5% |
| 营收同比 | -49.9% | — |
| 净利润同比 | -184.8% | 50.7% |
| 每股收益（稀释后） | $-0.06 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXSES
| Q4 25 | $9.1M | $4.6M | ||
| Q3 25 | $17.9M | $7.1M | ||
| Q2 25 | $15.7M | $3.5M | ||
| Q1 25 | $10.1M | $5.8M | ||
| Q4 24 | $18.2M | — | ||
| Q3 24 | $18.0M | — | ||
| Q2 24 | $13.5M | — | ||
| Q4 23 | $10.5M | — |
净利润PLXSES
| Q4 25 | $-5.5M | $-17.0M | ||
| Q3 25 | $2.4M | $-20.9M | ||
| Q2 25 | $164.0K | $-22.7M | ||
| Q1 25 | $-3.6M | $-12.4M | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $-2.2M | — | ||
| Q4 23 | $-6.0M | — |
毛利率PLXSES
| Q4 25 | 49.4% | 11.3% | ||
| Q3 25 | 53.4% | 51.1% | ||
| Q2 25 | 62.5% | 73.7% | ||
| Q1 25 | 19.1% | 78.7% | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q4 23 | 15.5% | — |
营业利润率PLXSES
| Q4 25 | -51.1% | -387.7% | ||
| Q3 25 | 11.9% | -262.0% | ||
| Q2 25 | 7.5% | -652.3% | ||
| Q1 25 | -41.0% | -401.7% | ||
| Q4 24 | 39.6% | — | ||
| Q3 24 | 22.2% | — | ||
| Q2 24 | -18.0% | — | ||
| Q4 23 | -53.5% | — |
净利率PLXSES
| Q4 25 | -60.3% | -373.5% | ||
| Q3 25 | 13.2% | -293.9% | ||
| Q2 25 | 1.0% | -642.2% | ||
| Q1 25 | -35.8% | -214.6% | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | — | ||
| Q2 24 | -16.4% | — | ||
| Q4 23 | -57.6% | — |
每股收益（稀释后）PLXSES
| Q4 25 | $-0.06 | $-0.05 | ||
| Q3 25 | $0.03 | $-0.06 | ||
| Q2 25 | $0.00 | $-0.07 | ||
| Q1 25 | $-0.05 | $-0.04 | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | — | ||
| Q2 24 | $-0.03 | — | ||
| Q4 23 | $-0.03 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $29.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $214.8M |
| 总资产 | $82.3M | $272.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXSES
| Q4 25 | $14.7M | $29.5M | ||
| Q3 25 | $13.6M | $35.3M | ||
| Q2 25 | $17.9M | $11.8M | ||
| Q1 25 | $19.5M | $56.1M | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $23.4M | — | ||
| Q4 23 | $23.6M | — |
股东权益PLXSES
| Q4 25 | $48.2M | $214.8M | ||
| Q3 25 | $52.9M | $228.2M | ||
| Q2 25 | $49.9M | $249.2M | ||
| Q1 25 | $45.2M | $269.9M | ||
| Q4 24 | $43.2M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $28.6M | — | ||
| Q4 23 | $33.6M | — |
总资产PLXSES
| Q4 25 | $82.3M | $272.6M | ||
| Q3 25 | $82.3M | $288.8M | ||
| Q2 25 | $78.5M | $290.5M | ||
| Q1 25 | $73.9M | $306.0M | ||
| Q4 24 | $73.4M | — | ||
| Q3 24 | $61.6M | — | ||
| Q2 24 | $91.5M | — | ||
| Q4 23 | $84.4M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $-10.4M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $-11.1M |
| 自由现金流率自由现金流/营收 | 17.8% | -243.7% |
| 资本支出强度资本支出/营收 | 4.4% | 15.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $-61.2M |
8季度趋势，按日历期对齐
经营现金流PLXSES
| Q4 25 | $2.0M | $-10.4M | ||
| Q3 25 | $-3.7M | $-14.3M | ||
| Q2 25 | $-5.2M | $-10.8M | ||
| Q1 25 | $-5.1M | $-22.8M | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $-3.6M | — | ||
| Q4 23 | $3.6M | — |
自由现金流PLXSES
| Q4 25 | $1.6M | $-11.1M | ||
| Q3 25 | $-4.2M | $-14.7M | ||
| Q2 25 | $-5.7M | $-11.6M | ||
| Q1 25 | $-5.4M | $-23.7M | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | — | ||
| Q4 23 | $3.3M | — |
自由现金流率PLXSES
| Q4 25 | 17.8% | -243.7% | ||
| Q3 25 | -23.7% | -206.9% | ||
| Q2 25 | -36.2% | -329.6% | ||
| Q1 25 | -53.0% | -410.0% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | — | ||
| Q4 23 | 31.9% | — |
资本支出强度PLXSES
| Q4 25 | 4.4% | 15.6% | ||
| Q3 25 | 2.8% | 6.0% | ||
| Q2 25 | 2.8% | 22.8% | ||
| Q1 25 | 3.0% | 15.8% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q4 23 | 2.4% | — |
现金转化率PLXSES
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SES
暂无分部数据
